Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis

Autor: John Lee, Elizabeth E. Hait, Paul Mitchell, Eitan Rubinstein

Publikováno v: Journal of Pediatric Gastroenterology & Nutrition. 66:395-397

BACKGROUND Eosinophilic esophagitis (EoE) is a clinicopathologic disorder characterized histologically by esophageal eosinophilia. Oral viscous budesonide (OVB) is an effective treatment with remission rates reported between 55% and 87%; however, top

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84efcf6a28e36598c90a33286cac6d6c
https://doi.org/10.1097/mpg.0000000000001718

Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis.

Autor: Syverson EP; Division of Gastroenterology and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts., Hait E; Division of Gastroenterology and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.

Publikováno v: Gastroenterology & hepatology [Gastroenterol Hepatol (N Y)] 2022 Apr; Vol. 18 (4), pp. 207-212.

Mechanical Skin Injury Promotes Food Anaphylaxis by Driving Intestinal Mast Cell Expansion.

Autor: Leyva-Castillo JM; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Galand C; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Kam C; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Burton O; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Gurish M; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Musser MA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Goldsmith JD; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Hait E; Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA., Nurko S; Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA., Brombacher F; International Center for Genetic Engineering and Biotechnology & University of Cape Town & South Africa Medical Research Council, South Africa., Dong C; Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China., Finkelman FD; Department of Internal Medicine and Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA., Lee RT; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA., Ziegler S; Immunology Program, Benaroya Research Institute, Seattle, WA, USA., Chiu I; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Austen KF; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Geha RS; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: raif.geha@childrens.harvard.edu.

Publikováno v: Immunity [Immunity] 2019 May 21; Vol. 50 (5), pp. 1262-1275.e4. Date of Electronic Publication: 2019 Apr 23.

Topical inhaled ciclesonide for treatment of eosinophilic esophagitis.

Autor: Lee JJ, Fried AJ, Hait E, Yen EH, Perkins JM, Rubinstein E

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2012 Oct; Vol. 130 (4), pp. 1011; author reply 1011-2.

Baby steps: determining the relationship between Crohn's activity and birth outcomes.

Autor: Hait E; Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2007 Dec; Vol. 13 (12), pp. 1578.